Lifecore Biomedical, Inc. reported a significant increase in financial performance for the three months ended September 30, 2025, with total revenues reaching $31.1 million, up 26% from $24.7 million in the same period last year. The growth was primarily driven by a 107% increase in hyaluronic acid (HA) manufacturing revenues, which rose to $9.4 million, and an 8% increase in contract development and manufacturing organization (CDMO) revenues, which totaled $21.7 million. The company's gross profit also improved, rising 45% to $7.8 million, resulting in a gross profit margin of 25%, compared to 21.8% in the prior year.
In terms of operational efficiency, Lifecore has made strides in reducing its operating expenses, which fell by 36% to $10.9 million, down from $17 million in the previous year. This reduction was largely attributed to a $5.9 million decrease in selling, general, and administrative expenses, which included lower legal and consulting costs. Research and development expenses also saw a modest decline of 10%, reflecting consistent levels of product development activities. Despite these improvements, the company reported a net loss of $10 million, a decrease from a loss of $16.2 million in the prior year, indicating a narrowing of losses.
Lifecore's balance sheet as of September 30, 2025, showed total assets of $235.2 million, a slight decrease from $239.3 million at the end of the previous fiscal period. The company’s cash and cash equivalents increased significantly to $18.9 million, up from $8.3 million, bolstered by the early repayment of a note receivable. However, total liabilities rose to $198.4 million, primarily due to an increase in debt related to the term loan credit facility with Alcon, which now stands at $179.6 million. The company remains in compliance with all financial covenants under its credit facilities.
Strategically, Lifecore has undergone a fiscal year change, transitioning from a fiscal year ending on the last Sunday of May to a calendar year ending December 31, effective for the fiscal period beginning May 26, 2025. This change aims to align the company’s reporting with industry standards and improve operational efficiencies. Additionally, Lifecore has completed a capacity expansion project that is expected to more than double its aseptic capacity, which is anticipated to enhance production capabilities and support future growth.
Looking ahead, Lifecore is focused on maximizing operational efficiencies and productivity through the implementation of a new enterprise resource planning (ERP) system, expected to go live in Q1 2026. The company is also actively managing its workforce productivity, which has improved by over 20% in the past year. Lifecore's management remains optimistic about future growth opportunities, although they acknowledge potential risks related to market conditions, customer demand, and regulatory compliance.
About LIFECORE BIOMEDICAL, INC. DE
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals and medical devices. It produces hyaluronic acid and viscous non-HA products, offering formulation, aseptic filling, and supply chain services across global markets. The company leverages proprietary fermentation, advanced manufacturing, and regulatory expertise to serve biopharmaceutical and biotech clients with high-quality, complex injectable solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.